News of Note—Sanofi, ImmusanT and more

newspaper
(Pixabay)

Here is some other vaccine news of note for the week:

> Dyadic will collaborate with Sanofi to explore how its C1 gene expression platform can be applied to Sanofi's vaccine and biologic offerings. The platform aims to speed development and reduce production costs for biologics. Release

> ImmusanT picked up funding from JDRF to work on a Type 1 diabetes vaccine. FierceBiotech article

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

> A drug combo containing a cancer vaccine showed promise against melanoma in a preclinical study. Release

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.